Palatin Technologies (PTN) investor relations material

Executive summary

• Advanced melanocortin-4 receptor (MC4R) agonist pipeline targets rare obesity and neuroendocrine disorders, with a focus on improved tolerability, usability, and long-term outcomes in chronic treatment settings.

• Lead peptide and oral small molecule programs are progressing toward IND submissions in late 2026 and early 2027, aiming for best-in-class selectivity and potency.

• Strategic partnerships and licensing agreements with Boehringer Ingelheim and Altanispac Labs have generated significant non-dilutive capital, upfront and milestone payments, and future royalty opportunities.

• The pipeline also includes programs for ocular, gastroenterology, and renal indications, with positive Phase 2 results in ulcerative colitis and diabetic nephropathy.

• Strategy emphasizes capital efficiency, leveraging partnerships, and advancing clinical programs for MC4R-related disorders.

Financial highlights

• Collaboration and license revenue was $3.9 million for Q3 FY2026 and $12.9 million for the nine months ended March 31, 2026, compared to no revenue in the prior year periods, mainly from the Altanispac and Boehringer Ingelheim agreements.

• Total operating expenses were $5.5 million for Q3 FY2026, up from $4.8 million year-over-year, mainly due to higher compensation and professional fees.

• Net loss for Q3 FY2026 was $1.4 million ($0.37 per share), a significant improvement from $4.8 million ($9.13 per share) in Q3 FY2025; nine-month net loss was $4.0 million versus $15.1 million year-over-year.

• Cash and cash equivalents stood at $10.2 million as of March 31, 2026, with $2.2 million in receivables expected by June 30, 2026.

• Net cash used in operations was $4.4 million for Q3 FY2026 and $10.8 million for the nine months, both improved year-over-year.

Outlook and guidance

• Existing cash, cash equivalents, and expected receivables are projected to fund operations through June 30, 2027; additional funding will be needed for future clinical trials and regulatory submissions.

• IND submissions for lead peptide and oral MC4R agonist programs are targeted for Q4 2026 and H1 2027, with Phase 1 trials to follow.

• Focus remains on developing best-in-class therapies with superior selectivity and patient compliance.